Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.47B P/E 20.53 EPS this Y 149.60% Ern Qtrly Grth -
Income 69.44M Forward P/E -15.27 EPS next Y -249.30% 50D Avg Chg -31.00%
Sales 199.76M PEG -40.73 EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 2.98 EPS next 5Y -0.60% 52W High Chg -61.00%
Recommedations 1.70 Quick Ratio 20.55 Shares Outstanding 46.59M 52W Low Chg 193.00%
Insider Own 0.05% ROA 9.45% Shares Float 24.83M Beta 1.21
Inst Own 89.98% ROE 19.84% Shares Shorted/Prior 2.52M/2.17M Price 31.45
Gross Margin 59.46% Profit Margin 34.76% Avg. Volume 428,482 Target Price 76.78
Oper. Margin 37.42% Earnings Date Feb 9 Volume 450,486 Change -6.76%

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

PRTA Chatroom

User Image oliveinvest Posted - 19 hours ago

Invest with an outcome based approach on $PRTA. Make up to 35.6% (41.0% annualized) and start to lose only if $PRTA drops by more than 24.0% through 12/16/2022. Sell 2 $35 puts 12/16/22 expiration https://o.oliveinvest.com/sk1g83

User Image BidaskBot Posted - 3 days ago

Prothena $PRTA BidaskScore is #Reiterated to StronglySold https://bidaskclub.com/news/company/2022-01-19/PRTA

User Image Patrick_Desjardins Posted - 4 days ago

$ZEV $PRTA $HYLN $LEV The mega cap high flyers like FAANG had dominated for so long. Now the focus is shifting, but it’s not to the neglected, oversold small caps with huge potential (like ZEV, Proterra). Investors are moving to the comfy, defensive value plays with good cash flow and low p/e’s. IBM, Costco, regional banks come to mind. So if you’re wondering why your small caps are still getting snubbed, that’s why. Investors want profits over potential right now. Just be patient. The quality small caps will have their day in the sun.

User Image oliveinvest Posted - 4 days ago

Invest with an outcome based approach on $PRTA. Make up to 44.3% (50.2% annualized) and start to lose only if $PRTA drops by more than 17.8% through 12/16/2022. Sell 1 $40 put Sell 1 $45 put 12/16/22 expiration https://o.oliveinvest.com/hyi3u3

User Image SheliaGomez1 Posted - 6 days ago

$PRTA Profit Factor of 8, trade profitability of 87.5%. 8 trades executed and buy signal in place. 15-min algo trading chart.

User Image oliveinvest Posted - 1 week ago

Invest with an outcome based approach on $PRTA. Make up to 50.5% (56.9% annualized) and start to lose only if $PRTA drops by more than 17.5% through 12/16/2022. Sell 2 $45 puts 12/16/22 expiration https://o.oliveinvest.com/pxymbc

User Image Patrick_Desjardins Posted - 1 week ago

$ZEV $PRTA $SOFI In case you missed it, my thoughts for buying on margin: https://m.youtube.com/watch?v=i-UMWGSkFh0&t=211s

User Image oliveinvest Posted - 1 week ago

Invest with an outcome based approach on $PRTA. Make a fixed 41.0% (45.9% annualized) and start to lose only if $PRTA drops by more than 16.2% through 12/16/2022. Buy 1 $30 put Sell 3 $40 puts 12/16/22 expiration https://o.oliveinvest.com/s0i1z2

User Image Invescent Posted - 1 week ago

$PRTA Data suggest that the overall analyst sentiment for PRTA is bullish. Simplify the way you research stocks with Invescent https://play.google.com/store/apps/details?id=org.invescent.invescent&hl=en_US&gl=US

User Image oliveinvest Posted - 1 week ago

Invest with an outcome based approach on $PRTA. Make up to 44.7% (49.3% annualized) and start to lose only if $PRTA drops by more than 7.0% through 12/16/2022. Buy 1 $35 call Sell 1 $45 call Sell 1 $45 put 12/16/22 expiration https://o.oliveinvest.com/zcjfz0

User Image tickeron Posted - 1 week ago

Does this make you nervous? $PRTA enters a Downtrend as Momentum Indicator dropped below the 0 level on January 5, 2022. View odds for this and other indicators: https://srnk.us/go/3332367

User Image STCKPRO Posted - 1 week ago

$PRTA NEW ARTICLE : Prothena (PRTA) Gets a Buy Rating from JMP Securities https://www.stck.pro/news/PRTA/21327996

User Image oliveinvest Posted - 1 week ago

Invest with an outcome based approach on $PRTA. Accelerate gains by 3.4x and make up to 27.8% (50.7% annualized) on $PRTA through 08/19/2022. Buy 1 $35 call Sell 1 $40 call Sell 1 $40 put 8/19/22 expiration https://o.oliveinvest.com/5p9dt7

User Image EarningsInsider Posted - 1 week ago

Oppenheimer Sets Prothena FY2026 Earnings Estimates at $0.10 EPS. https://www.marketbeat.com/x/1161697 $PRTA

User Image Newsfilter Posted - 1 week ago

$PRTA Form SC 13D/A (general statement of acquisition of beneficial ownership) filed with the SEC https://newsfilter.io/a/f9e0d0c81fee3cc4db9eb3ff7bd96bda

User Image Quantisnow Posted - 1 week ago

$PRTA 📜 SEC Form SC 13D/A filed by Prothena Corporation plc (Amendment) https://quantisnow.com/insight/2255097?s=s 45 seconds delayed.

User Image Aigner_Andreas Posted - 2 weeks ago

#DeathCross $PRTA at 37.24 R22 HiLo 39% T1Y 82 buy 1.7 DIV N/A #Prothena C #stocks #trading #finance #market

User Image Insider_Analysis Posted - 2 weeks ago

$PRTA Capital, Llc Ecor1 bought 300,000 shares [Very High Conviction] www.insider-analysis.com/search_transactions.php?ticker=TABLE_PRTA

User Image Invescent Posted - 2 weeks ago

$PRTA Data suggest that the overall analyst sentiment for PRTA is bullish. Simplify the way you research stocks with Invescent https://play.google.com/store/apps/details?id=org.invescent.invescent&hl=en_US&gl=US

User Image theflynews Posted - 2 weeks ago

Meet Prothena: Fly exclusive interview with CEO Gene Kinney - $PRTA - http://thefly.com/permalinks/entry.php/PRTAid3440427

User Image MichaelCanuck Posted - 2 weeks ago

$PRTA - Interesting that AH buy of $11 mil from a director. That's after nothing but insider sells since June. Might take a small bite.

User Image shortablestocks Posted - 2 weeks ago

$PRTA is short sale restricted for 2022-01-13. https://www.shortablestocks.com/?PRTA

User Image MarketBeatInsiderTrades Posted - 2 weeks ago

Prothena Major Shareholder Ecor1 Capital, Llc Buys $11,250,000.00 in $PRTA https://www.marketbeat.com/i/492369

User Image cctranscripts Posted - 2 weeks ago

Major owner of Prothena Corp plc just picked up 300,000 shares https://www.conferencecalltranscripts.com/summary/?id=10314567 $PRTA

User Image Quantisnow Posted - 2 weeks ago

$PRTA 📜 SEC Form 4: Ecor1 Capital, Llc bought $11,250,300 worth of Ordinary Shares (300,000 units at $37.50) https://quantisnow.com/insight/2248770?s=s 45 seconds delayed.

User Image fla Posted - 2 weeks ago

$PRTA [15s. delayed] filed SEC form 4: 10% Owner EcoR1 Capital, LLC: Acquired 300,000 of Ordinary Shares at price $37.5 on 2022-01-12, in https://s.flashalert.me/qyofu

User Image risenhoover Posted - 2 weeks ago

Insider EcoR1 Capital, LLC reports buying 300,000 shares of $PRTA for a total cost of $11,250,300.00 https://fintel.io/n/us/prta/ecor1-capital?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Newsfilter Posted - 2 weeks ago

$PRTA $11,250,000.00 of shares acquired by Ecor1 Capital, Llc (10% Owner), reported in a new form 4 filed with the SEC https://newsfilter.io/a/e0785251f3c319acef365b068454e3d3

User Image macroaxis Posted - 2 weeks ago

$PRTA - Is downward rally slipping https://www.macroaxis.com/stock-analysis/PRTA/Prothena-Corp #stocks #earnings

User Image quantcha Posted - 2 weeks ago

Big Loser Alert: Trading today's -12.3% move in PROTHENA CORPORATION PLC ORDIN $PRTA https://wp.me/p5bLGB-fsYP

Analyst Ratings
JMP Securities Market Outperform Nov 19, 21
RBC Capital Outperform Sep 30, 21
Oppenheimer Outperform Sep 27, 21
Fox Advisors Overweight Sep 20, 21
Cantor Fitzgerald Overweight Sep 17, 21
Oppenheimer Outperform Sep 14, 21
Oppenheimer Outperform Aug 9, 21
RBC Capital Outperform Jul 19, 21
Citigroup Buy Jul 13, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
EcoR1 Capital, LLC 10% Owner 10% Owner Jan 12 Buy 37.501 300,000 11,250,300 11,584,280 01/12/22
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Nov 23 Option 15.04 4,519 67,966 4,519 11/26/21
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Nov 23 Sell 57.97 4,519 261,966 11/26/21
Malecek Michael J See Remarks See Remarks Nov 19 Option 10.27 10,000 102,700 10,000 11/19/21
Malecek Michael J See Remarks See Remarks Nov 19 Sell 55 10,000 550,000 11/19/21
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Nov 01 Option 15.04 10,000 150,400 10,000 11/03/21
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Nov 01 Sell 56.72 10,000 567,200 11/03/21
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Oct 20 Option 22.43 23,000 515,890 23,000 10/22/21
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Oct 20 Sell 60.95 23,000 1,401,850 10/22/21
HENNEY CHRISTOPHER S Director Director Jul 12 Option 10.28 23,892 245,610 6,392 07/12/21
HENNEY CHRISTOPHER S Director Director Jul 12 Sell 57.61 23,892 1,376,418 07/12/21
HENNEY CHRISTOPHER S Director Director Jun 29 Option 16.43 12,000 197,160 12,000 06/29/21
EcoR1 Capital, LLC 10% Owner 10% Owner Feb 25 Buy 21.54 55,200 1,189,008 10,159,280 02/25/21
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Feb 19 Option 6.41 7,540 48,331 7,540 02/19/21
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Feb 19 Sell 25.5 7,540 192,270 02/19/21